The Treatment of Crimean-Congo Hemorrhagic Fever With High-dose Methylprednisolone, Intravenous Immunoglobulin, and Fresh Frozen PlasmaErduran, Erol MD; Bahadir, Aysenur MD; Palanci, Nil MD; Gedik, Yusuf MDJournal of Pediatric Hematology/Oncology: January 2013 - Volume 35 - Issue 1 - p e19–e24 doi: 10.1097/MPH.0b013e3182706444 Online Articles: Clinical and Laboratory Observations Abstract Author Information Crimean-Congo hemorrhagic fever (CCHF) is an acute tick-borne disease caused by Nairovirus, and it is sometimes characterized by reactive hemophagocytic histiocytosis (HLH). The reasons for reactive HLH are macrophage-activating syndrome and disseminated intravascular coagulation due to cytokine storm, liver dysfunction, and endothelial damage by the virus. In this study, the effectiveness of high-dose methylprednisolone (HDMP) (5 to 30 mg/kg/d), fresh frozen plasma (FFP), and intravenous immunoglobulin (IVIG) was investigated in patients with CCHF associated with reactive HLH. Twelve patients with CCHF in association with reactive HLH were included in the study. The patients were successfully treated with HDMP to suppress the macrophage activation, FFP to treat disseminated intravascular coagulation, and IVIG to treat severe thrombocytopenia. No patients received ribavirin. Fever reduced in 1.6±0.8 days, WBC count increased above 4.500/µL in 4.0±2.4 days, platelet count increased above 150.000/µL in 8.5±2.5 days, and D-dimer level decreased under 1 mcg/dL in 5.8±3.6 days. Consequently, HDMP, FFP, and IVIG may be effective in patients with CCHF associated with reactive HLH during hemorrhagic period of the disease. Departments of *Pediatric Haematology †Pediatrics, Medical School, Karadeniz Technical University, Trabzon, Turkey The authors declare no conflict of interest. Reprints: Erol Erduran, MD, KTU Lojmanlari 35/2, Trabzon 61080, Turkey (e-mail: firstname.lastname@example.org). Received November 16, 2011 Accepted August 22, 2012 Copyright © 2013 Wolters Kluwer Health, Inc. All rights reserved.